| pubmed-article:3057923 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C1457887 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C0009010 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C0028768 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C0457454 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C1444662 | lld:lifeskim |
| pubmed-article:3057923 | lifeskim:mentions | umls-concept:C0332156 | lld:lifeskim |
| pubmed-article:3057923 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:3057923 | pubmed:dateCreated | 1989-1-10 | lld:pubmed |
| pubmed-article:3057923 | pubmed:abstractText | To evaluate the need for maintenance drug therapy in patients with obsessive-compulsive disorder, the authors assessed 21 patients with obsessive-compulsive disorder who manifested sustained improvement during 5 to 27 months of clomipramine treatment and who agreed to participate in a double-blind discontinuation study. Of 18 patients who completed the study, 16 had substantial recurrence of obsessive-compulsive symptoms by the end of the 7-week placebo period. In addition, 11 had a significant increase in depressive symptoms. Treatment duration before discontinuation of clomipramine was not related to the frequency or severity of obsessive-compulsive or depressive symptom appearance. These findings suggest that prolonged drug treatment may be warranted for obsessive-compulsive disorder. | lld:pubmed |
| pubmed-article:3057923 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3057923 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3057923 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3057923 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:3057923 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3057923 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3057923 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:3057923 | pubmed:issn | 0002-953X | lld:pubmed |
| pubmed-article:3057923 | pubmed:author | pubmed-author:MurphyD LDL | lld:pubmed |
| pubmed-article:3057923 | pubmed:author | pubmed-author:ZoharJJ | lld:pubmed |
| pubmed-article:3057923 | pubmed:author | pubmed-author:NeisLL | lld:pubmed |
| pubmed-article:3057923 | pubmed:author | pubmed-author:Zohar-Kadouch... | lld:pubmed |
| pubmed-article:3057923 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3057923 | pubmed:volume | 145 | lld:pubmed |
| pubmed-article:3057923 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3057923 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3057923 | pubmed:pagination | 1521-5 | lld:pubmed |
| pubmed-article:3057923 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:meshHeading | pubmed-meshheading:3057923-... | lld:pubmed |
| pubmed-article:3057923 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3057923 | pubmed:articleTitle | Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. | lld:pubmed |
| pubmed-article:3057923 | pubmed:affiliation | Laboratory of Clinical Science, NIMH, Bethesda, MD 20892. | lld:pubmed |
| pubmed-article:3057923 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3057923 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3057923 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3057923 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3057923 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3057923 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3057923 | lld:pubmed |
